Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MIN-101 MR Formulations and Food Effect
NCT03038646Phase 1Completed
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Nov 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of roluperidone in schizophrenia (4 arms), sponsored by Minerva Neurosciences, Inc. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 3 more. Started Nov 2016; status: completed.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03038646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038646.